Article
Hematology
Martin G. Klatt, Tao Dao, Zhiyuan Yang, Jianying Liu, Sung Soo Mun, Megan M. Dacek, Hanzhi Luo, Thomas J. Gardner, Christopher Bourne, Leila Peraro, Zita E. H. Aretz, Tanya Korontsvit, Michael Lau, Michael G. Kharas, Cheng Liu, David A. Scheinberg
Summary: Mass spectrometry identified a non-immunogenic HLA ligand as a target for CAR T-cell therapy, which showed broad effectiveness against multiple cancer types, particularly hematologic cancers, and had no toxic effects on healthy cells.
Article
Oncology
Marco Ventin, Giulia Cattaneo, Luke Maggs, Jingyu Jia, Shahrzad Arya, Soldano Ferrone, Xinhui Wang, Cristina R. Ferrone
Summary: Adoptive cell therapy with CAR-modified T cells has shown promising clinical results in hematological malignancies, but solid cancers face obstacles to this success. Investigating and counteracting escape mechanisms is crucial. Literature evidence supports the potential of radiotherapy to enhance solid tumors' susceptibility to CAR T cell therapy. Multiple mechanisms may contribute to this, including reduced proliferation and upregulation of antigens.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Ayda Baghery Saghchy Khorasani, Amir-Mohammad Yousefi, Davood Bashash
Summary: CAR NK cells have attracted attention as a viable alternative to CAR T cells due to their MHC-independency, shorter life expectancy, potential for off-the-shelf immune product creation, and potent antitumor properties. This article provides an updated review of the differences between CAR T and CAR NK cells, current enhancements in CAR NK design, sources for collecting NK cells, and strategies for transducing CARs to NK cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Chemistry, Multidisciplinary
Ruxing Fu, Hongjun Li, Ruoxin Li, Kyle McGrath, Gianpietro Dotti, Zhen Gu
Summary: CAR T cells show promise in cancer immunotherapy, but have limited clinical success in solid tumors, leading to exploration of strategies to enhance their efficacy. Altering the tumor microenvironment is crucial, with a focus on future development directions.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Multidisciplinary Sciences
Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R. M. van den Brink, Ming D. Li, He Huang
Summary: This study compares the gut microbiome diversity and composition during different phases of CAR-T therapy and finds that it is associated with patient response to therapy and occurrence of immune-related adverse effects.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
Summary: The use of allogeneic CAR4-DNTs as adoptive cell therapy for T-cell malignancies is effective. CAR4-DNTs can effectively target T-ALL and PTCL and have superior cytotoxicity compared to empty-vector transduced DNTs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Bouthaina Dabaja, Michael Spiotto
Summary: Over the past half-century, the role of radiotherapy has shifted from directly killing cancer cells to stimulating anti-tumor immune responses. This interplay between radiation, the tumor microenvironment, and the immune system is crucial in cancer immunology. While most studies have focused on solid tumors, there is growing understanding of this interaction in hematological malignancies. This review highlights recent advances in immunotherapy and adoptive cell therapy and emphasizes the importance of incorporating radiation therapy into the treatment of hematological malignancies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Breeshey Roskams-Hieter, Hyun Ji Kim, Pavana Anur, Josiah T. Wagner, Rowan Callahan, Elias Spiliotopoulos, Charles Ward Kirschbaum, Fehmi Civitci, Paul T. Spellman, Reid F. Thompson, Khashayar Farsad, Willscott E. Naugler, Thuy T. M. Ngo
Summary: cfRNA sequencing enables the discovery of mRNA biomarkers in plasma specific to cancer types and precancerous conditions, demonstrating diagnostic potential.
NPJ PRECISION ONCOLOGY
(2022)
Review
Oncology
Jun Meng, XiaoQin Wu, Zhen Sun, RenDe Xun, MengSi Liu, Rui Hu, JianChao Huang
Summary: This study summarized the efficacy and safety of three CAR-T cell products in treating hematologic malignancies, showing promising results in patients with different pathological subtypes and clinical characteristics, but also highlighting the potential for severe toxicity in certain situations. Additional data on these products are needed to benefit a broader patient population.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Duy T. Nguyen, Elizabeth Ogando-Rivas, Ruixuan Liu, Theodore Wang, Jacob Rubin, Linchun Jin, Haipeng Tao, William W. Sawyer, Hector R. Mendez-Gomez, Matthew Cascio, Duane A. Mitchell, Jianping Huang, W. Gregory Sawyer, Elias J. Sayour, Paul Castillo
Summary: This article discusses the important role of the tumor microenvironment in CAR-T cell therapy and explains the advantages and limitations of preclinical models.
Review
Oncology
Hidefumi Hiramatsu
Summary: Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and though the long-term survival rate is high at 90%, about 20% of patients experience relapse and need second-line treatment. The introduction of immunotherapy, including CAR-T cell therapy, has revolutionized the treatment of relapsed and refractory ALL. However, CAR-T cell therapy can cause specific adverse events, and the biggest challenge remains preventing relapse. Overall, the success of CD19 CAR-T cell therapy against B cell malignancies has led to further research into its potential for other hematologic malignancies.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Immunology
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu
Summary: CAR-T cell therapy has shown remarkable success in antitumor treatments, particularly against hematological malignancies. The development of universal CAR-T (UCAR-T) cell therapy may overcome current limitations, with a focus on safety, efficiency, and potential complementary immune cells. The landscape and prospects of UCAR-T cell therapy are explored through a comprehensive overview of progress and challenges.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell & Tissue Engineering
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Fatemeh Rahbarizadeh
Summary: CAR-T therapy has been successful in treating various types of relapsed/refractory B-cell malignancies, but faces challenges when combating T-cell malignancies, including fratricide, T-cell aplasia, and product contamination. Further research and improvements are needed to address these obstacles and enhance CAR-T therapy in T-cell malignancies.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Oncology
Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Perez-Martinez, Manel Juan, Cristina Eguizabal
Summary: CAR-T cells have shown promising results in treating relapsed or refractory hematological cancers, but their limitations have led to the emergence of CAR-NK cells as a good alternative. CAR-NK cells demonstrate efficacy with fewer side-effects, positioning them as a viable option for CAR-based treatments.
Article
Multidisciplinary Sciences
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao
Summary: For many years, the main methods of cancer treatment have been surgery, chemotherapy, and radiation therapy. However, these methods often have limited success. Immunotherapy, particularly CAR-T therapy, has emerged as a promising approach for treating tumors. CAR-T therapy uses the patient's own T cells to target and kill tumor cells, showing significant success in the treatment of hematological tumors.
Meeting Abstract
Oncology
Fatima Khan, Smriti Gurung, Hyun-Kyung Jung, Moon-Chang Baek, Yong Woo Choi, In San Kim, Byung Heon Lee
Meeting Abstract
Oncology
Smriti Gurung, Fatima Khan, Soo-Woong Lee, Jaewon Yoon, Byungheon Lee
Article
Oncology
Md Enamul Haque, Fatima Khan, Lianhua Chi, Smriti Gurung, Sri Murugan Poongkavithai Vadevoo, Rang-Woon Park, Dong-Kyu Kim, Sang Kyoon Kim, Byungheon Lee
CANCER RESEARCH AND TREATMENT
(2019)
Review
Chemistry, Medicinal
Murugan Poongkavithai Vadevoo, Smriti Gurung, Fatima Khan, Md. Enamul Haque, Gowri Rangaswamy Gunassekaran, Lianhua Chi, Uttapol Permpoon, Byungheon Lee
ARCHIVES OF PHARMACAL RESEARCH
(2019)
Article
Engineering, Biomedical
Smriti Gurung, Fatima Khan, Gowri Rangaswamy Gunassekaran, Jae Do Yoo, Sri Murugan Poongkavithai Vadevoo, Uttapol Permpoon, Sang-Hyun Kim, Ha-Jeong Kim, In-San Kim, Hyeonjeong Han, Ji-Ho Park, Soyoun Kim, Byungheon Lee
Article
Medicine, Research & Experimental
Uttapol Permpoon, Fatima Khan, Sri Murugan Poonkavithai Vadevoo, Smriti Gurung, Gowri Rangaswamy Gunassekaran, Min-Jong Kim, Sang-Hyun Kim, Peti Thuwajit, Byungheon Lee
MOLECULAR PHARMACEUTICS
(2020)
Review
Cell Biology
Wenjing Xuan, Fatima Khan, Charles David James, Amy B. Heimberger, Maciej S. Lesniak, Peiwen Chen
Summary: The article summarizes how circadian rhythms affect cancer cell biology and interact with the tumor microenvironment, discussing the mutual influence between cancer cells and the TME, and indicating that these studies can inform the development of novel clock-oriented therapeutic strategies.
TRENDS IN CELL BIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Lizhi Pang, Fatima Khan, Madeline Dunterman, Peiwen Chen
Summary: Glioblastoma (GBM) is a common and lethal brain tumor, and the symbiotic interaction between immune cells and GBM cells plays a critical role in tumor progression and therapy resistance. Targeting the tumor-immune symbiosis pharmacologically has emerged as a promising strategy for GBM treatment.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2022)
Article
Oncology
Wenjing Xuan, Wen-Hao Hsu, Fatima Khan, Madeline Dunterman, Lizhi Pang, Derek A. Wainwright, Atique U. Ahmed, Amy B. Heimberger, Maciej S. Lesniak, Peiwen Chen
CANCER IMMUNOLOGY RESEARCH
(2022)
Review
Oncology
Anshika Goenka, Fatima Khan, Bhupender Verma, Priyanka Sinha, Crismita C. Dmello, Manasi P. Jogalekar, Prakash Gangadaran, Byeong-Cheol Ahn
Summary: Tumor development and metastasis are influenced by the complex interactions between cancer cells and their microenvironment, which includes stromal cells and extracellular matrix components. Understanding the signaling pathways involved in these interactions is crucial for developing effective intervention strategies. This review provides a comprehensive analysis of the diverse signaling pathways in the tumor microenvironment, highlighting the latest preclinical and clinical studies and their underlying biology.
CANCER COMMUNICATIONS
(2023)
Article
Immunology
Lizhi Pang, Madeline Dunterman, Songlin Guo, Fatima Khan, Yang Liu, Erfan Taefi, Atousa Bahrami, Changiz Geula, Wen-Hao Hsu, Craig Horbinski, Charles David James, Peiwen Chen
Summary: TFPI2 promotes glioblastoma stem cell self-renewal and connects stemness to microglia immunosuppression. Targeting TFPI2-mediated glioblastoma stem cell-microglia symbiosis inhibits tumor growth and synergizes with anti-PD1 therapy in glioblastoma.
Review
Medicine, Research & Experimental
Fatima Khan, Lizhi Pang, Madeline Dunterman, Maciej S. Lesniak, Amy B. Heimberger, Peiwen Chen
Summary: Glioblastoma (GBM) is the most aggressive tumor in the central nervous system and has a highly immunosuppressive tumor microenvironment (TME). Tumor-associated macrophages and microglia (TAMs) are dominant immune cells in the GBM TME and contribute to immunosuppression. Recent progress in single cell technologies allows for precise characterization of TAMs and identification of new TAM subpopulations with specific tumor-modulating functions in GBM. This review discusses TAM heterogeneity and plasticity in the TME and summarizes current potential therapeutic approaches targeting TAMs in GBM. The use of single cell technologies and functional studies is expected to accelerate the development of novel and effective TAM targeted therapeutics for GBM patients.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Oncology
Lizhi Pang, Fatima Khan, Amy B. Heimberger, Peiwen Chen
Summary: This review discusses the symbiotic interactions between cancer cells and myeloid cells in glioblastoma and their impact on tumor progression and immunotherapy. It highlights the strategies to intercept this co-dependency for improved treatment outcomes.
Article
Medicine, Research & Experimental
Fatima Khan, Smriti Gurung, Gowri Rangaswamy Gunassekaran, Sri Murugan Poongkavithai Vadevoo, Lianhua Chi, Uttapol Permpoon, Md. Enamul Haque, Yun-Ki Lee, Soo-Woong Lee, Soyoun Kim, Byungheon Lee
Summary: NLN and NEW peptides bind preferentially to CD44v6-high cells, internalize and inhibit metastasis-related signaling pathways, reducing metastases by targeting tumors, and induce apoptosis by guiding KLAKLAKKLAKLAK pro-apoptotic peptide, showing promising potential for metastasis inhibition and tumor growth suppression.